Allogene Therapeutics, Inc.
IMPROVED T CELL COMPOSITIONS AND METHODS

Abstract:

The present invention provides compositions and methods that downregulate major histocompatibility class I molecule cell surface expression, and uses of such compositions and methods for improving the functional activities of isolated T cells (e.g., gene-modified antigen-specific T cells, such as chimeric antigen receptor T (CAR-T) cells). In particular, the present invention provides methods and compositions for bolstering the therapeutic efficacy of CAR-T cells.